Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Novartis
Express Scripts
Moodys
Julphar
Mallinckrodt
Dow
Merck
Medtronic
Farmers Insurance

Generated: October 17, 2017

DrugPatentWatch Database Preview

Patents Expiring in February 2023

« Back to Dashboard
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Aralez Pharms
YOSPRALA
aspirin; omeprazole
TABLET, DELAYED RELEASE;ORAL205103-001Sep 14, 2016RXYesNo► Subscribe► SubscribeY
Aralez Pharms
YOSPRALA
aspirin; omeprazole
TABLET, DELAYED RELEASE;ORAL205103-002Sep 14, 2016RXYesYes► Subscribe► SubscribeY
Horizon Pharma Usa
VIMOVO
esomeprazole magnesium; naproxen
TABLET, DELAYED RELEASE;ORAL022511-001Apr 30, 2010ABRXYesYes► Subscribe► SubscribeY RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
Aralez Pharms
YOSPRALA
aspirin; omeprazole
TABLET, DELAYED RELEASE;ORAL205103-002Sep 14, 2016RXYesYes► Subscribe► SubscribeY
Horizon Pharma Usa
VIMOVO
esomeprazole magnesium; naproxen
TABLET, DELAYED RELEASE;ORAL022511-002Apr 30, 2010ABRXYesNo► Subscribe► SubscribeY RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
Aralez Pharms
YOSPRALA
aspirin; omeprazole
TABLET, DELAYED RELEASE;ORAL205103-001Sep 14, 2016RXYesNo► Subscribe► SubscribeY
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-004Dec 10, 2007RXYesNo► Subscribe► Subscribe FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-001Feb 23, 2007RXYesNo► Subscribe► Subscribe FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-005Dec 10, 2007RXYesNo► Subscribe► SubscribeY
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-006Dec 10, 2007RXYesNo► Subscribe► SubscribeY INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Federal Trade Commission
Deloitte
Johnson and Johnson
Medtronic
Chubb
McKesson
Farmers Insurance
Julphar
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot